Updates in Antiplatelet Agents Used in Cardiovascular Diseases

Conclusions:
In the last 5 years, newer antiplatelet agents, including prasugrel and ticagrelor, have been demonstrated to reduce recurrent cardiovascular events compared to standard therapy and, however, also caused increase bleeding in selected patient populations. Newer agents including shorter acting P2Y12 inhibitor or antiplatelets that target other receptors are being evaluated to improve/maintain therapeutic efficacy yet minimize the risk of bleeding.

Source: Journal of Cardiovascular Pharmacology and Therapeutics - November 8, 2013 Category: Cardiology Authors: Cheng, J. W. M. Tags: Cardiovascular Pharmacology Core Reviews Source Type: research